AU2017313753B2 - GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma - Google Patents

GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma Download PDF

Info

Publication number
AU2017313753B2
AU2017313753B2 AU2017313753A AU2017313753A AU2017313753B2 AU 2017313753 B2 AU2017313753 B2 AU 2017313753B2 AU 2017313753 A AU2017313753 A AU 2017313753A AU 2017313753 A AU2017313753 A AU 2017313753A AU 2017313753 B2 AU2017313753 B2 AU 2017313753B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
compounds
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017313753A
Other languages
English (en)
Other versions
AU2017313753A1 (en
Inventor
Alexander E. Arnold
James M. Cook
Charles W. Emala
Gloria FORKUO
Rajwana JAHAN
Revathi KODALI
Guanguan LI
Douglas C. Stafford
Michael Rajesh Stephen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
UWM Research Foundation Inc
Original Assignee
Columbia University in the City of New York
UWM Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York, UWM Research Foundation Inc filed Critical Columbia University in the City of New York
Publication of AU2017313753A1 publication Critical patent/AU2017313753A1/en
Application granted granted Critical
Publication of AU2017313753B2 publication Critical patent/AU2017313753B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017313753A 2016-08-16 2017-08-16 GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma Active AU2017313753B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662375694P 2016-08-16 2016-08-16
US62/375,694 2016-08-16
US201662427771P 2016-11-29 2016-11-29
US62/427,771 2016-11-29
PCT/US2017/047185 WO2018035246A1 (en) 2016-08-16 2017-08-16 Gaba(a) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma

Publications (2)

Publication Number Publication Date
AU2017313753A1 AU2017313753A1 (en) 2019-03-07
AU2017313753B2 true AU2017313753B2 (en) 2022-01-27

Family

ID=59714151

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017313753A Active AU2017313753B2 (en) 2016-08-16 2017-08-16 GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma

Country Status (8)

Country Link
US (2) US11447495B2 (enExample)
EP (1) EP3500573B1 (enExample)
JP (1) JP7013446B2 (enExample)
CN (1) CN109790170B (enExample)
AU (1) AU2017313753B2 (enExample)
CA (1) CA3033964A1 (enExample)
ES (1) ES2895965T3 (enExample)
WO (1) WO2018035246A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3167543A1 (en) * 2020-03-31 2021-10-07 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as gaba a gamma1 pams
EP3901155A1 (en) * 2020-04-20 2021-10-27 F. Hoffmann-La Roche AG New benzodiazepine derivatives as gaba a gamma1 pam
CN118019742A (zh) 2021-09-29 2024-05-10 豪夫迈·罗氏有限公司 作为GABA A γ1 PAM的新颖苯并二氮杂䓬衍生物
KR20240073892A (ko) 2021-10-06 2024-05-27 에프. 호프만-라 로슈 아게 Gaba a gamma1 수용체의 양성 알로스테릭 조절인자로서의 벤조디아제핀 유도체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226768A (en) * 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US20060003995A1 (en) * 2004-06-30 2006-01-05 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US20120295892A1 (en) * 2011-04-28 2012-11-22 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
WO2014047413A1 (en) * 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA755418B (en) 1974-09-11 1977-06-29 Hoffmann La Roche Diazepine derivatives
US4125726A (en) 1977-03-11 1978-11-14 Hoffmann-La Roche Inc. Imidazo[1,5-a][1,4]benzodiazepines
US4401597A (en) 1978-05-15 1983-08-30 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
US4238610A (en) 1979-12-20 1980-12-09 Hoffmann-La Roche Inc. Intermediates for the production of imidazobenzodiazepines
ZA845757B (en) 1983-08-25 1985-04-24 Hoffmann La Roche Benzodiazepine derivatives
US5317018A (en) 1992-06-09 1994-05-31 Armin Walser Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy
TW349100B (en) 1994-11-11 1999-01-01 Hoffmann La Roche Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines
CA2184802C (en) 1995-10-10 2007-07-31 Karl-Heinz Bender Process for manufacture of imidazo benzodiazepine derivatives
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US20010014738A1 (en) 1999-06-30 2001-08-16 Madhup K. Dhaon Process for the preparation of imidazodiazepine intermediates
US6512114B1 (en) 1999-06-30 2003-01-28 Abbott Laboratories Process for the preparation of Midazolam
US6262260B1 (en) 2000-03-23 2001-07-17 Abbott Laboratories Process for the preparation of midazolam
US7119196B2 (en) 2002-03-28 2006-10-10 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
CA2568394A1 (en) 2004-06-09 2005-12-29 Avanir Pharmaceuticals Heterocyclic derivatives for treatment of hyperlipidemia and related diseases
EP1888594A2 (en) 2005-05-16 2008-02-20 Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits
US8119629B2 (en) 2007-10-03 2012-02-21 Bristol-Meyers Squibb Company Carboxamide GABAA α2 modulators
US20100261711A1 (en) 2009-03-20 2010-10-14 Wisys Technology Foundation Selective anticonvulsant agents and their uses
IT1399764B1 (it) 2010-05-04 2013-05-03 F S I Fabbrica Italiana Sint Procedimento per la sintesi di 4h-imidazo [1,5-a][1,4]benzodiazepine, in particolare di midazolam.
BR112013030095A2 (pt) 2011-05-23 2019-09-24 Elan Pharm Inc inibidores de atividade de lrrk2 cinase
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
CN103204838B (zh) 2012-01-13 2017-06-09 北京盛诺基医药科技有限公司 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用
CN103319486B (zh) 2012-03-22 2017-10-10 徐州市心血管病研究所 合成4H‑咪唑并[1,5‑a][1,4]苯二氮卓,特别是咪达唑仑的方法
WO2017161370A1 (en) 2016-03-18 2017-09-21 Uwm Reseach Foundation, Inc. Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226768A (en) * 1979-05-29 1980-10-07 Hoffmann-La Roche Inc. Process for the preparation of imidazobenzodiazepines
US20060003995A1 (en) * 2004-06-30 2006-01-05 Wisys Technology Foundation, Inc. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
US20120295892A1 (en) * 2011-04-28 2012-11-22 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
WO2014047413A1 (en) * 2012-09-21 2014-03-27 Uwm Research Foundation, Inc. Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
del Pozo, C. et al.; Synthesis, 2697-2703 (2004). doi: 10.1055/s-2004-831243 *
Walser, A. et al.; J. Heterocyclic Chem., 23, 1303-1314 (1986). doi: 10.1002/JHET.5570230509 *
Watjen, F. et al.; J. Med. Chem., 32, 2282-2291 (1989). doi: 0.1021/JM00130A010 *

Also Published As

Publication number Publication date
EP3500573A1 (en) 2019-06-26
JP2019528267A (ja) 2019-10-10
US12054491B2 (en) 2024-08-06
WO2018035246A1 (en) 2018-02-22
US20230103216A1 (en) 2023-03-30
CN109790170A (zh) 2019-05-21
AU2017313753A1 (en) 2019-03-07
CA3033964A1 (en) 2018-02-22
ES2895965T3 (es) 2022-02-23
US11447495B2 (en) 2022-09-20
BR112019003065A2 (pt) 2019-05-21
US20210284649A1 (en) 2021-09-16
CN109790170B (zh) 2022-08-02
JP7013446B2 (ja) 2022-02-15
EP3500573B1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
US12054491B2 (en) Substituted benzo[f]imidazo[1,5-a][1,4]diazepines as GABA(a) receptor modulators
JP5874878B2 (ja) 複素二環スピロ化合物又はその薬学的に許容される塩、これらの化合物を含む医薬組成物、および哺乳類のアルツハイマー病及びインスリン抵抗性症候群及び２型糖尿病を治療するための薬剤の調整における、これらの化合物の利用
US9597342B2 (en) GABAergic receptor subtype selective ligands and their uses
EP4028401B1 (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
JP6141331B2 (ja) グリコーゲンシンターゼキナーゼ３ベータ阻害剤としての１ｈ−インダゾール−３−カルボキサミド化合物
EA018620B1 (ru) ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1
TW200911817A (en) Polycyclic guanine derivatives and methods of use thereof
JP7125495B2 (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
CN114591352B (zh) 一种三唑并哒嗪类化合物及其应用
US20190300534A1 (en) Gabaergic ligands and their uses
CN110573497A (zh) 组蛋白脱乙酰基酶抑制剂
HUP0400819A2 (hu) 4-(Bifenil-karbonil-amino)-piperidin-származékok, mint MTP inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US11427582B2 (en) Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use
US9879020B2 (en) GABAA agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
JP5673676B2 (ja) イミダゾ［１，２−ａ］ピリジン誘導体
BR112019003065B1 (pt) Compostos moduladores do receptor gaba(a) ou sais farmaceuticamente aceitável dos mesmos, composição farmacêutica e forma de dosagem unitária compreendendo ditos compostos e usos terapêuticos dos mesmos
WO2024220874A2 (en) Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs)
JPH04364180A (ja) イソインドリノン誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)